CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes

Sulfonylureas (SUs) are predominantly metabolized by cytochrome p450 2C9 (CYP2C9) and cytochrome p450 2C19 (CYP2C19) enzymes. CYP2C9 polymorphisms are associated with greater treatment response and hypoglycemic risk in SU users. However, there are no large scale pharmacogenetic studies investigating...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ke, Yang, Aimin, Shi, Mai, Tam, Claudia C. H., Lau, Eric S. H., Fan, Baoqi, Lim, Cadmon K. P., Lee, Heung Man, Kong, Alice P. S., Luk, Andrea O. Y., Tomlinson, Brian, Ma, Ronald C. W., Chan, Juliana C. N., Chow, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297921/
https://www.ncbi.nlm.nih.gov/pubmed/34656068
http://dx.doi.org/10.1002/cpt.2446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297921/
https://www.ncbi.nlm.nih.gov/pubmed/34656068
http://dx.doi.org/10.1002/cpt.2446

Ejemplares similares